Flura-seq identifies organ-specific metabolic adaptations during early metastatic colonization

Abstract

Metastasis-initiating cells dynamically adapt to the distinct microenvironments of different organs, but these early adaptations are poorly understood due to the limited sensitivity of in situ transcriptomics. We developed fluorouracil-labeled RNA sequencing (Flura-seq) for in situ analysis with high sensitivity. Flura-seq utilizes cytosine deaminase (CD) to convert fluorocytosine to fluorouracil, metabolically labeling nascent RNA in rare cell populations in situ for purification and sequencing. Flura-seq revealed hundreds of unique, dynamic organ-specific gene signatures depending on the microenvironment in mouse xenograft breast cancer micrometastases. Specifically, the mitochondrial electron transport Complex I, oxidative stress and counteracting antioxidant programs were induced in pulmonary micrometastases, compared to mammary tumors or brain micrometastases. We confirmed lung metastasis-specific increase in oxidative stress and upregulation of antioxidants in clinical samples, thus validating Flura-seq's utility in identifying clinically actionable microenvironmental adaptations in early metastasis. The sensitivity, robustness and economy of Flura-seq are broadly applicable beyond cancer research.

Data availability

Sequencing data have been deposited in GEO under accession codes GSE93605 and GSE118937.

The following data sets were generated
The following previously published data sets were used

Article and author information

Author details

  1. Harihar Basnet

    Cancer Biology and Genetics Program, Memorial Sloan-Kettering Cancer Center, New York, United States
    Competing interests
    Harihar Basnet, Has filed for patent for Flura-seq method (PCT/US18/22092).
  2. Lin Tian

    Cancer Biology and Genetics Program, Memorial Sloan-Kettering Cancer Center, New York, United States
    Competing interests
    No competing interests declared.
  3. Karuna Ganesh

    Cancer Biology and Genetics Program, Memorial Sloan-Kettering Cancer Center, New York, United States
    Competing interests
    No competing interests declared.
  4. Yun-Han Huang

    Cancer Biology and Genetics Program, Memorial Sloan-Kettering Cancer Center, New York, United States
    Competing interests
    No competing interests declared.
  5. Danilo G Macalinao

    Cancer Biology and Genetics Program, Memorial Sloan-Kettering Cancer Center, New York, United States
    Competing interests
    No competing interests declared.
  6. Edi Brogi

    Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, United States
    Competing interests
    No competing interests declared.
  7. Lydia Finley

    Cell Biology Program, Memorial Sloan-Kettering Cancer Center, New York, United States
    Competing interests
    No competing interests declared.
  8. Joan Massagué

    Cancer Biology and Genetics Program, Memorial Sloan-Kettering Cancer Center, New York, United States
    For correspondence
    j-massague@ski.mskcc.org
    Competing interests
    Joan Massagué, Reviewing editor, eLife. Has filed for patent for Flura-seq method (PCT/US18/22092). Serves in the scientific advisory board and owns company stock in Scholar Rock.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-9324-8408

Funding

National Institutes of Health (P01-CA094060)

  • Joan Massagué

Damon Runyon Cancer Research Foundation (DR-12998)

  • Harihar Basnet

Department of Defense (W81XWH-12-0074)

  • Joan Massagué

National Institutes of Health (T32-CA009207)

  • Karuna Ganesh

National Institutes of Health (T32-GM07739)

  • Yun-Han Huang

National Institutes of Health (K08-CA230213)

  • Karuna Ganesh

National Institutes of Health (F30-CA203238)

  • Yun-Han Huang

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: Mouse experiments were performed following the protocols approved by the MSKCC Institutional Animal Care and Use Committee (IACUC) (#99-09-032).

Copyright

© 2019, Basnet et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 6,025
    views
  • 850
    downloads
  • 57
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Harihar Basnet
  2. Lin Tian
  3. Karuna Ganesh
  4. Yun-Han Huang
  5. Danilo G Macalinao
  6. Edi Brogi
  7. Lydia Finley
  8. Joan Massagué
(2019)
Flura-seq identifies organ-specific metabolic adaptations during early metastatic colonization
eLife 8:e43627.
https://doi.org/10.7554/eLife.43627

Share this article

https://doi.org/10.7554/eLife.43627

Further reading

    1. Cancer Biology
    Han V Han, Richard Efem ... Richard Z Lin
    Research Article

    Most human pancreatic ductal adenocarcinoma (PDAC) are not infiltrated with cytotoxic T cells and are highly resistant to immunotherapy. Over 90% of PDAC have oncogenic KRAS mutations, and phosphoinositide 3-kinases (PI3Ks) are direct effectors of KRAS. Our previous study demonstrated that ablation of Pik3ca in KPC (KrasG12D; Trp53R172H; Pdx1-Cre) pancreatic cancer cells induced host T cells to infiltrate and completely eliminate the tumors in a syngeneic orthotopic implantation mouse model. Now, we show that implantation of Pik3ca−/− KPC (named αKO) cancer cells induces clonal enrichment of cytotoxic T cells infiltrating the pancreatic tumors. To identify potential molecules that can regulate the activity of these anti-tumor T cells, we conducted an in vivo genome-wide gene-deletion screen using αKO cells implanted in the mouse pancreas. The result shows that deletion of propionyl-CoA carboxylase subunit B gene (Pccb) in αKO cells (named p-αKO) leads to immune evasion, tumor progression, and death of host mice. Surprisingly, p-αKO tumors are still infiltrated with clonally enriched CD8+ T cells but they are inactive against tumor cells. However, blockade of PD-L1/PD1 interaction reactivated these clonally enriched T cells infiltrating p-αKO tumors, leading to slower tumor progression and improve survival of host mice. These results indicate that Pccb can modulate the activity of cytotoxic T cells infiltrating some pancreatic cancers and this understanding may lead to improvement in immunotherapy for this difficult-to-treat cancer.

    1. Cancer Biology
    2. Immunology and Inflammation
    Almudena Mendez-Perez, Andres M Acosta-Moreno ... Esteban Veiga
    Short Report

    In this study, we present a proof-of-concept classical vaccination experiment that validates the in silico identification of tumor neoantigens (TNAs) using a machine learning-based platform called NAP-CNB. Unlike other TNA predictors, NAP-CNB leverages RNA-seq data to consider the relative expression of neoantigens in tumors. Our experiments show the efficacy of NAP-CNB. Predicted TNAs elicited potent antitumor responses in mice following classical vaccination protocols. Notably, optimal antitumor activity was observed when targeting the antigen with higher expression in the tumor, which was not the most immunogenic. Additionally, the vaccination combining different neoantigens resulted in vastly improved responses compared to each one individually, showing the worth of multiantigen-based approaches. These findings validate NAP-CNB as an innovative TNA identification platform and make a substantial contribution to advancing the next generation of personalized immunotherapies.